Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 433Carcinoma, Non-Small-Cell Lung 372Neoplasms 326Prostatic Neoplasms 244Leukemia, Myeloid, Acute 231Multiple Myeloma 229Neoplasm Metastasis 215Melanoma 202Lung Neoplasms 178Leukemia 172Lymphoma 170Colorectal Neoplasms 157Pancreatic Neoplasms 151Lymphoma, Non-Hodgkin 150Recurrence 149Ovarian Neoplasms 146Leukemia, Lymphocytic, Chronic, B-Cell 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 131Myelodysplastic Syndromes 121Carcinoma, Renal Cell 121Lymphoma, Large B-Cell, Diffuse 111Lymphoma, Follicular 108Brain Neoplasms 101Squamous Cell Carcinoma of Head and Neck 96Head and Neck Neoplasms 96Glioblastoma 92Urinary Bladder Neoplasms 88Carcinoma, Hepatocellular 80Hodgkin Disease 73Colonic Neoplasms 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Has results × Metastatic Solid Tumors × Clear all
NCT03573544 2024-02-22

This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.

OBI Pharma, Inc

Phase 1/2 Terminated
54 enrolled 16 charts
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡